Primary Cells Market

The global size of primary cells market in terms of revenue was estimated to be worth USD 1.7 billion in 2023 and is poised to reach USD 2.8 billion by 2028, growing at a CAGR of 10.5% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The growth of this market can be attributed to factors such as the is the growing advantages of primary human cells over cell lines, rising growth in pharmaceutical & biotechnology industries, increasing demand for monoclonal antibodies, Government investments for cell-based research, and increasing cancer research.

Attractive Opportunities in the Primary Cells Market

To know about the assumptions considered for the study, Request for Free Sample Report

Primary Cells Market Dynamics

DRIVER: Advantages of primary human cells over cell lines

Primary human cells have a wide range of advantages over in vitro cell lines; they provide reliable tissue-specific responses in a biologically relevant microenvironment. Drug responses in cell lines may not provide false responses in a cellular context. Moreover, primary human cells are cost-effective and help in reducing the expenditure on animal models required for in vivo studies. Pre-screened primary cells help in representing signaling in vivo very closely. Owing to this, pharmaceutical and biotechnology companies, as well as CROs, are increasingly shifting to primary human cells for their lead identification and optimization processes in drug discovery. Some of the key advantages of primary human cells include physiological relevance, genetic diversity, and tumor microenvironment representation, among others.

The conventional methods of toxicity and drug safety assessment involve animal testing, which is expensive, time-consuming, and low throughput. Thus, primary human cells present a preferable alternative for biochemical assays and animals because of their physiological relevance; inherent virtues; and ability to provide efficient, cost-effective, and accelerated drug discovery solutions. The use of primary cultures also tackles many ethical objections raised against animal experiments and allows for experimentation on human tissues, which is otherwise limited to in vitro studies. These advantages of human and animal primary cells are driving their adoption among end users and thereby fueling market growth.

RESTRAINT: Concerns regarding primary cell culture contamination

Contamination is a significant concern in primary cell cultures, as it can negatively impact experimental results, introduce variability, and compromise the reliability of research findings. Some of the main concerns regarding primary cell culture contamination include bacterial and fungal contamination, viral contamination, cross-contamination, and mycoplasma contamination. To minimize the risk of contamination, it is essential to follow good aseptic techniques and implement appropriate quality control measures. Implementing strict aseptic practices, performing regular monitoring, and testing, and using authenticated cells can minimize the risk of contamination in primary cell cultures, ensuring more reliable and reproducible experimental outcomes.

OPPORTUNITY: Advancing biomedical research using primary cells in 3D cultures

The use of primary cells in 3D cultures has advanced biomedical research by providing a more physiologically relevant model that better mimics the complexity and architecture of human tissues. Primary cells in 3D cultures have significantly advanced biomedical research by providing more physiologically relevant models for studying diseases, drug discovery, toxicity assessment, and personalized medicine. These models have the potential to bridge the gap between traditional cell culture and in vivo studies, leading to more accurate predictions and improved translation of research findings to clinical applications. Hence, the increasing use of primary cells with 3D cultures in various R&D activities is expected to influence the demand for primary cells in the coming years. This is expected to provide a wide range of growth opportunities for players in the market.

CHALLENGE: Sourcing and availability of primary cells

Obtaining high-quality primary cells can be a challenge due to the limited availability of specific tissue types and donor variability. Sourcing primary cells from diverse patient populations and obtaining consent for tissue donation can be logistically challenging. Additionally, the availability of certain primary cell types may be limited, making it difficult to meet the demand for specific research needs. Sourcing and availability of primary cells can be a challenge due to several factors, such as tissue acquisition, donor variability, tissue preservation, and transport, and the limited availability of specific cell types. Addressing these challenges requires collaborations between researchers, tissue banks, and regulatory bodies to ensure a streamlined process for tissue acquisition, storage, and distribution. Efforts to expand tissue repositories, establish partnerships with healthcare institutions, and promote tissue donation can help enhance the availability of primary cells. Additionally, advances in techniques for cryopreservation, tissue storage, and transport can improve the accessibility and quality of primary cells, overcoming some of the challenges associated with sourcing and availability.

In 2022, by origin, human primary cells segment dominated the primary cells industry.

On the basis of origin, the primary cells market is divided into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the market. Factors responsible for the growth of the segment include the extensive use of human primary cells for studying human cancerous cell models, as well as in toxicology studies. The driving factors for the human market also include the demand for accurate disease models, advancements in research and drug discovery, the rise of regenerative medicine, safety testing requirements, the increasing burden of chronic diseases, technological innovations, ethical considerations, and collaborative initiatives within the scientific community.

Hematopoietic cells segment accounted for the largest share in the primary cells industry, by type in 2022.

On the basis of type, the primary cells market is divided into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2022, the hematopoietic cells segment accounted for the largest market share. Factors such as use of Hematopoietic cell transplants and to develop novel cancer therapies to treat blood cancers and other disorders of the immune system are responsible for the segment growth. Hepatocytes, due to their increasing demand in toxicological and pharmacological studies, are expected to witness the highest growth in the market.

In 2022, the pharmaceutical & biotechnology companies, and CROs segment accounted for the largest share of the global primary cells industry, by end user.

On the basis of end users, the primary cells market is segmented into pharmaceutical & biotechnology companies, and CROs, academic & research institutes, and other end users. In 2022, pharmaceutical & biotechnology companies and CROs accounted for the largest share of the market, mainly due to the high adoption of primary cells in cell-based experiments and cancer research in pharmaceutical & biotechnology companies and CROs, as well as the increasing number of R&D facilities globally.

In 2022, North America is the largest region for primary cells industry.

The global primary cells market is divided in four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America accounted for the largest share of the market, followed by Europe. Due to established clusters in North America and Europe, these regions are the preferred locations for drug discovery. Asia Pacific is expected to register the highest growth during the forecast period due to an increase in populations and a rise in the burden of diseases.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), and Corning Incorporated (US).

Scope of the Primary Cells Industry

This report categorizes the primary cells market to forecast revenue and analyze trends in each of the following submarkets:

By Origin

• Human Primary Cells
• Animal Primary Cells

By Type

• Hematopoietic Cells
• Dermatocytes
• Gastrointestinal Cells
• Hepatocytes
  • Cryopreserved Hepatocytes
  • Fresh Hepatocytes
• Lung Cells
• Renal Cells
• Heart Cells
• Musculoskeletal Cells
• Other Primary Cells

By End User

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Rest of the World

Recent Developments of Primary Cells Industry

• In June 2023, iXCells Biotechnologies entered into an agreement with Tebubio to enhance the distribution of the company’s products throughout Europe.
• In March 2022, Lonza launched human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, expanding

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst